FDA clears Diagnostic Hybrids' rapid respiratory virus test
This article was originally published in Clinica
Diagnostic Hybrids' test for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) has received 510(k) clearance from the US FDA. The D3 FastPoint L-DFA RSV/MPV identification kit identifies the viruses, which are the most common causes of lower respiratory infection in young children, within 25 minutes. It is the only FDA-cleared product that can detect both RSV and hMPV antigens simultaneously, the Athens, Ohio company claimed, adding that other rapid, point-of-care tests do not generally identify MPV. Like the firm's two other D3 FastPoint respiratory virus tests, the diagnostic uses monoclonal antibodies to detect the viruses in nasopharyngeal swabs, aspirates and washes.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.